翰森制药(03692.HK) 公布,昕越(伊奈利珠单抗注射液)的第三项上市许可申请(BLA)获国家药品监督管理局受理,用于治疗全身型重症肌无力(gMG)成人患者。
伊奈利珠单抗是靶向CD19 B细胞消耗性抗体,并于2022年3月14日获准在中国上市,适用于抗水通道蛋白4(AQP4)抗体阳性的视神经脊髓炎谱系障碍(NMOSD)成人患者的治疗,其后该药于今年3月4日,第二项BLA获药监局受理,用于治疗免疫球蛋白G4相关性疾病(IgG4-RD)。(sl/u)(港股报价延迟最少十五分钟。沽空资料截至 2025-05-30 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.